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Abstract 
I n   t h i s   s t u d y ,   w e   c h a r a c t e r i z e d   t h e   i n t r a t u m o r a l   e x p r e s s i o n   o f   I L -17 and CD8
+ T I L s   i n   g a s t r i c  
adenocarcinoma patients after resection and determined the correlation between the survival 
probability of gastric adenocarcinoma patients and the expression of IL-17 in tumor. Ex-
p r e s s i o n   o f   I L -17 and CD8 was assessed by immunohistochemistry, and the prognostic effects 
of  intratumoral  IL-17 expression and CD8
+ TILs were evaluated by Cox regression and 
Kaplan-Meier analysis. Immunohistochemical detection revealed the presence of IL-17 and 
CD8
+ cells in gastric adenocarcinoma tissue samples (90.6%, 174 out of 192 patients and 
96.9%, 186 out of 192 patients, respectively). We have also found that intratumoral IL-17 
expression was significantly correlat e d   w i t h   a g e   ( p=0.004) and that the number of CD8
+ TILs 
was significantly correlated with UICC staging (p=0.012) and the depth of tumor invasion 
(p=0.022 ) .   T h e   f i v e -year overall survival probability among patients intratumorally expressing 
higher levels of IL-17 was significantly better than those expressing lower levels of IL-17 
(p=0.036). Multivariate Cox proportional hazard analyses revealed that intratumoral IL-17 
expression (HR: 0.521; 95% CI: 0.329-0.823; p=0.005)   w as a n   i n dependent factor affecting the 
five-year overall survival probability. W e   c o n c l u d e   t h a t   l ow levels of intratumoral IL-17 ex-
pression may indicate poor prognosis in gastric adenocarcinoma patients. 
Key words: IL-17, intratumoral expression, gastric carcinoma, prognostic indicator 
Introduction 
Gastric  carcinoma  is  one  of  the  most  common 
types  of  cancer.  Recently,  incidence  and  mortality 
rates  of  gastric  carcinoma  have  declined  overall. 
However,  in  Asian  countries,  such  as  Japan,  China, 
and  other  developing  countries,  gastric  carcinoma 
remains the most common form of cancer. Traditional 
therapies, such as surgery, chemotherapy, and radio-
therapy,  play  an important  role  in  treating  different Int. J. Biol. Sci. 2011, 7 
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kinds and stages of gastric carcinoma [1, 2]. In spite of 
this,  determining  the  prognosis  for  a  patient  with 
g a s t r i c   c a r c i n o m a   h a s   n o t   y e t   b e e n   w e l l   s t u d i e d .   I t   i s  
generally agreed that there is a correlation between 
the infiltration of immune cells within a tumor  and 
tumor  development.  Therefore,  the  distribution  of 
various types of immune cells detected in gastric car-
cinoma may provide useful information for a patient’s 
prognosis. 
Interleukin-17  (IL-17)  is  a  CD4  T  cell–derived 
proinﬂammatory  cytokine.  Many  studies  have  re-
vealed that IL-17 plays an active role in the develop-
ment of inflammation, GVHD and autoimmune  dis-
eases [3-5]. The relationship between cancer and IL-17 
has been investigated. An increase in the number of 
IL-17-p o s t i v e   c e l l s   i n   t u m o r s   w a s   d e t e c t e d   i n   p r o s t a t e  
cancer,  ovarian  cancer,  and  hepatocellular  cancer 
[6-9]. Furthermore, some researchers have shown that 
t h e   n u m b e r   o f   I L -17-p o s t i v e   c e l l s   c o r r e l a t e s   w i t h   t u-
mor  development  and  patient  prognosis.  Although 
IL-1 7   m R N A   h a s   b e e n   d e t e c t e d   i n   t u m o r s   i n   p a t i e n t s  
w i t h   g a s t r i c   c a n c e r   [ 1 0 ] ,   t h e   d i s t r i b u t i o n   o f  
IL-17-p o s t i v e   c e l l s   w i t h i n   t h e   t u m o r   a n d   t h e  relation-
ship between IL-1 7   a n d   p r o g n o s i s   h a v e   n o t   y e t   b e e n  
investigated.  In  this  report,  we  examined  the  intra-
t u m o r a l   e x p r e s s i o n   o f   I L -17 and CD8 by immunohis-
tochemistry, and correlated it with the clinical data of 
gastric  adenocarcinoma  patients.  We  evaluated  the 
prognostic  effects  of  intratumoral  IL-17low  or  high  ex-
pression and  CD8+ TILs  (tumor-inﬁltrating lympho-
cytes) by Cox regression and Kaplan-Meier analysis. 
Material and Methods 
Patients and tissue specimens 
Paraffin-embedded samples were obtained from 
192 gastric adenocarcinoma patients who underwent 
s u r g i c a l   o p e r a t i o n s   a t   t h e   S u n   Y a t -sen  University 
Cancer Center, Guangzhou, China, between 2002 and 
2005.  Patients  with  autoimmune  diseases  were  ex-
cluded. None of the patients had received anticancer 
treatment prior to surgery. There were 129 male and 
6 3   f e m a l e   p a t i e n t s   w i t h   a   m e d i a n   a g e   o f   5 8   y e a r s  
(range,  17-85  years).  The  follow-u p   d a t e s   o f   t h e   p a-
tients  in  this  study  are  available  and  complete.  The 
median follow-up for the entire cohort was 61 months 
(range 0.3-81.6 months). There were 79 cases of stage 
I-II and 113 cases of stage III-IV cancer according to 
the TNM classification for gastric cancer pTNM stag-
ing  system  (International  Union  Against  Cancer, 
UICC). Each lesion was graded histologically accord-
ing to the WHO classification criteria. Overall survival 
(OS) was defined as the interval between the date of 
s u r g e r y   a n d   d a t e   o f   d e a t h   o r   t h e   l a s t   k n o w n   f o l-
low-u p .   A l l   s a m p l e s   w e r e   c o d e d   a n o n y m o u s l y   i n   a c-
cordance with local ethical guidelines (as stipulated 
by  the  Declaration  of  Helsinki).Written  informed 
consent was obtained, and the protocol was approved 
b y   t h e   R e v i e w   B o a r d   o f   t h e   S u n   Y a t -sen  University 
Cancer Center. 
Immunohistochemistry 
Formalin-fixed,  paraffin-embedded  samples 
w e r e   c u t   t o   a   thickness of 5 μm. Each tissue section 
was  deparaffinized  and  rehydrated  with  graded 
ethanol. For antigen retrieval, the slides were boiled in 
E D T A   ( 1   m M ;   p H   8 . 0 )   f o r   1 5   m i n   i n   a   m i c r o w a v e  
oven.  Endogenous  peroxidase  activity  was  blocked 
w i t h   a   0 . 3 %   h y d r o g en peroxide solution for 10 min at 
r o o m   t e m p e r a t u r e .   A f t e r   r i n s i n g   w i t h   P B S ,   s l i d e s   w e r e  
incubated overnight at 4°C with respective primary 
antibodies which include goat anti-human IL-17 po-
lyclonal antibody (R&D systems; dilution 1/300) and 
mouse  anti-human  CD8  monoclonal  antibody 
(Zhongshan  Golden  Bridge  Biotech,  Beijing,  China; 
d i l u t i o n   1 / 1 0 0 ) .   A f t e r   t h r e e   w a s h e s   i n   P B S ,   s e c t i o n s  
were  incubated  with  biotinylated  anti-goat  or  an-
ti-mouse  secondary  antibody  (Zhongshan  Golden 
Bridge Biotech, Beijing, China) respectively for 30 min 
a t   r o o m   t e m p e r a t u r e .   I m m u n o s t a i n i n g   w a s   p e r-
f o r m e d   u s i n g   t h e   E n v i s i o n   S y s t e m   w i t h   d i a m i n o b e n-
zidine (DakoCytomation, Glostrup, Denmark). Final-
l y ,   t h e   s i g n a l   w a s   d e v e l o p e d   w i t h  
3,3'-diaminobenzidine tetrahydrochloride (DAB), and 
all  of  the  slides  were  counterstained  with  hematox-
y l i n .   D a t a   w e r e   o b t a i n e d   b y   m a n u a l l y   c o u n t i n g   p o s i-
tively stained cells in five separate areas of intratu-
m o r a l   r e g i o n s   u n d e r   4 0 0 ×   h i g h -power magnification. 
D e n s i t i e s   w e r e   d e t e r m i n e d   b y   c o m p u t i n g   t h e   m e a n  
number  of  positively  stained  cells  per  high  power 
microscopic  field  (HPF).  Mouse  IgG1  (DAKO)  and 
n o r m a l   g o a t   I g G   ( S a n t a )   w e r e   u s e d   a s   n e g a t i v e   c o n t r o l  
stains . 
Statistical analysis 
Descriptive statistics were expressed as the mean 
±   S D   o r   m e d i a n   ( r a n g e ) .   T h e   m e d i a n   value of immu-
nohistochemically  detected  variables  of  IL-17  and 
CD8 was used as cut-off  for defining t h e   T I L   s u b-
groups  in  our  results  as  previously  described  [11]. 
Chi-squared  tests  or  Fisher  exact  tests  were  used  to 
assess the relationship between  IL-17  and CD8 and 
clinic  pathological  features.  Correlations  between 
IL-17 and CD8 were determined by the Pearson cor-
relation coefficient. Prognostic factors were examined 
by bivariable and multivariable analyses using Kap-
lan-Meier  methodology  and  Cox  proportional  ha-
zards  model.  A two-sided  p v a l u e   <   0 . 0 5   w a s   c o n s i-Int. J. Biol. Sci. 2011, 7 
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dered statistically significant. All statistical analyses 
were  performed  with  SPSS  software  (version  16.0; 
SPSS Inc., Chicago, IL, USA). 
Results  
Study population 
The patients’ characteristics are presented in Ta-
ble 1. Of the 192  patients examined, 82(42.8%) were 
dead before the end of the  observation period.  The 
median  age  of  the  study  population  was  58  years 
(range17–85  years).  The  majority  of  patients  (146) 
presented with serous histology (76.1%). The median 
follow-up for the entire cohort was 61 months (range 
0.3-81.6  months).  The  5-year  survival  for  the  entire 
study population was 57.2%. 
 
 
 
Table 1 Clinical characteristics of 192 patients with gastric 
adenocarcinoma  
Characteristics  Number (％) 
Age, years   
median  58 
range  17-85 
Gender   
male  129(67.2) 
female  63(32.8) 
Tumor (T) stage   
T1  3(1.6) 
T2  38(19.7) 
T3  145(75.1) 
T4  6(3.1) 
Lymphoid Nodal (N) status   
N0  51(26.4) 
N1  92(47.7) 
N2  40(20.7) 
N3  9(4.7) 
Distant metastasis (M) status   
M0  176(91.2) 
M1  16(8.3) 
TNM stage   
Ⅰ  8(4.1) 
Ⅱ  71(36.8) 
Ⅲ  94(48.7) 
Ⅳ  19(9.8) 
Death   
no  110(57.2) 
yes  82(42.8) 
Histologic grade   
well  6(3.1) 
moderate  40(20.8) 
poor  146(76.1) 
Recurrence   
no  175(90.7) 
yes  17(8.8) 
 
Immunohistochemical characteristics 
The occurrences of IL-17 and CD8 positive cells 
were 90.6% (174 of  192)  and  96.9%  (186  of  192),  re-
spectively.  IL-17  immunostaining  was  mostly  loca-
lized to the cytoplasm whereas CD8 positive staining 
w a s   m o s t l y   o b s e r v e d   a t   t h e   p l a s m a   m e m b r a n e. CD8 
positive staining is characteristic of cytotoxic T lym-
phocytes (Figure 1 and Table 2). 
 
Table 2. Descriptive statistics of immunohistochemical 
variables 
Variables  Mean  SE  Median Range 
CD8+ TIL  15.53  0.78  13  0-60 
Intratumoral IL-17-producing cells 3.42  0.238  2.5  0-21 
 
 
Relationship between CD8
+ TIL, intratumoral 
IL-17 expression and clinic pathological features 
of patients with gastric adenocarcinoma 
CD8+  TILs  were  significantly  related  to  UICC 
staging  (p=0.012)  and  depth  of  tumor  invasion 
(p=0.022)  (Table  3).  IL-1 7   e x p r e s s i o n   w a s   r e l a t e d   t o  
age  (p=0.004)  but  not  to  gender,  histologic  grade, 
l y m p h   n o d e   m e t a s t a s i s ,   d e p t h   o f   i n v a s i o n ,   o r   U I C C  
staging (Table 3).  
Correlation between intratumoral IL-17 expres-
sion, CD8
+ TILs
 and patient survival  
The  prognostic  value  of  IL-17  expression  and 
CD8+ TILs on gastric adenocarcinoma patient survival 
was  evaluated  between  patients  with  high  and  low 
IL-17  expression  and  CD8 +  TIL  numbers.  Using  a 
Kaplan-Meier curve assessment, we found that low 
IL-17 expression in tumor tissue was an independent 
predictor of poor prognosis in gastric adenocarcinoma 
patients.  The  five-year  overall  survival  probability 
among patients expressing higher levels of IL-17 was 
significantly better than those expressing lower levels 
of IL-17 (p=0.036) (Figure 2). There was no significant 
correlation  between  the  number  of  CD8 +  TILs  and 
patient survival (p=0.366) (Figure 3). 
Univariate and multivariate analysis of prognosis 
variables in gastric adenocarcinoma patients 
 T o   i d e n t i f y   t h e   v a riables of potential prognostic 
significance  in  all  patients  with  gastric  adenocarci-
noma, univariate and multivariate analyses were car-
r i e d   o u t   u s i n g   t h e   C o x   p r o p o r t i o n a l   h a z a r d   m o d e l   t o  
compare the impact of the expression levels of IL-17 
and CD8+ TILs and other clinical pathological para-
m e t e r s   o n   t h e   p r o g n o s i s   o f   1 9 2   g a s t r i c   a d e n o c a r c i n o-
ma patients. Univariate analysis showed that IL-17 
expression, tumor size, and recurrence were signifi-Int. J. Biol. Sci. 2011, 7 
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cant prognostic factors (Table 4). Multivariate analysis 
determined that IL-17 expression was an independent 
predictor  of  survival  (p=0.005),   a s   w as  recurrence 
(p=0.000) .   T h e   r e l a t i v e   r i s k   i n   p a t i e n t s   w i t h   l o w   l e v e l s  
of IL-17 was 0.521 times greater than that of patients 
with higher expression of IL-17 (Table 4). 
Correlation analysis between intratumoral ex-
pression of IL-17 and CD8
+ TILs 
 T h r o u g h   c o r r e l a t i o n   a n a l y s i s ,   w e   f o u n d   n o   s i g-
nificant correlation between intratumoral expression 
of IL-17 and CD8+ TILs (Figure 4). 
 
Table 3. Correlations between CD8+ TILs, intratumoral IL-17 expression and clinic pathological features of patients with 
gastric adenocarcinoma  
Variables  CD8+ T cells  p value  IL-17-postive cells  p value 
low  high  low  high 
Gender             
male  68  61    63  66   
female  27  36  0.221  29  34  0.760 
Age             
≥60  46  39    51  34   
＜60  49  58  0.309  41  66  0.004a 
Tumor size             
≥4 cm  72  66    69  69   
＜4 cm  23  31  0.263  23  31  0.422 
Depth of invasion             
T1-T2  27  14    20  21   
T3-T4  68  83  0.022a  72  79  1.000 
UICC staging             
Ⅰ-Ⅱ  47  66    65  58   
Ⅲ-Ⅳ  48  31  0.012a  37  42  0.883 
Lymph node metastasis             
no  28  23    23  28   
yes  67  74  0.415  69  72  0.744 
Histologic grade             
well  3  3    4  2   
moderate  26  14    17  23   
poor  66  80  0.085  71  75  0.510 
             
ap value<0.05 
 
Table 4. Univariate analyses of variables associated with survival and recurrence 
Variables  Univariate analysis  Multivariate analysis 
HR  95% CI  p value  HR  95% CI  p value 
CD8+ TIL (low v high)  0.818   0.529-1.266  0.367        
Intratumoral IL-17-postive cells (low v high)  0.628   0.405-0.974  0.038a  0.521   0.329-0.823  0.005a 
Age, years (≥60 v ＜60)  1.326   0.857-2.050  0.205        
Gender (male v female)  0.984   0.622-1.556  0.945        
Tumor size (≥4cm v ＜4cm)  2.190   1.230-3.898  0.008a  1.755   0.974-3.163  0.061  
Lymph node metastasis (no v yes)  1.019   0.620-1.676  0.940        
Depth of invasion ( T1-T2 v T3-T4)  0.968   0.573-1.635  0.903        
Recurrence (no v yes)  5.142  2.899-9.119  0.000a  5.585  3.035-10.779  0.000a 
Histologic grade(well/moderate/poor)  0.817   0.557-1.198  0.302           
HR Hazard ratio, CI confidence interval              
ap value<0.05 
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Figure 1 Intratumoral expression of IL-17 and CD8
+ TIL detection. Consecutive sections were used for immu-
nohistochemical analysis of CD8
+ T I L   ( A ,   B )   a n d   I L -1 7   e x p r e s s i o n   ( C ,   D )   ( A ,   C   200× magnification; B, D 400×magnification). 
 
 
Figure 2 Patients expressing higher levels of IL-17 intratumorally show significantly better five-year overall 
survival (p=0.036). Survival curves of 192 gastric adenocarcinoma patients with different IL-17 expression are shown. 
Kaplan-M e i e r   s u r v i v a l   c u r v e s   f o r   h i g h   i n t r a t u m o r a l   e x p r e s s i o n   o f   I L -17 group were significantly different (p=0.036, log-rank 
test) from low IL-17 expression group in 192 gastric adenocarcinoma patients. 
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Figure 3 Lack of significant correlation between the number of CD8
+ TILs and patient survival (p=0.366). 
Survival curves of 192 gastric adenocarcinoma patients with various numbers of CD8
+ T I L s   a r e   s h o w n .   Kaplan-Meier survival 
curves for larger number of CD8
+ TIL group were not significantly different (p=0.366 ,   l o g -rank test) from smaller number of 
CD8
+ TIL group in 192 gastric adenocarcinoma patients. 
 
 
Figure 4 Correlation analyses between intratumoral expression of IL-17 and CD8
+ TILs. Linear regression 
analysis showed no correlation between intratumoral expression of IL-17 and CD8
+ TILs (r=0.068, p=0.348). 
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G a s t r i c   c a n c e r   i s   o n e   o f   t h e   m o s t   c o m m o n   c a n-
cers in Asia, including China. Despite the reduction in 
m o r t a l i t y   r a t e s   d u e   t o   b o t h   e a r l i e r   d e t e c t i o n   a n d   i m-
proved  therapies,  gastric  cancer  still  poses  a  major 
t h r e a t   t o   h u m a n   h e a l t h .   I t   w o u l d   t h e r e f o r e   b e   v a l u a b l e  
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inflammation,  GVHD  and  autoimmune  diseases 
[12-1 4 ] .   R e c e n t   s t u d y   h a s   s h o w n   t h a t   t h i s   e f f e c t o r   T  
c e l l   s u b s e t   i s   a l s o   i n v o l v e d   i n   t u m o r   i m m u n ology. An 
increase  in  IL-17-positive cells has  been  observed  in 
prostate cancer and hepatocellular cancers, and there 
are correlations between IL-17 and patient survival in 
ovarian cancer and small cell lung cancer [15-17]. In 
this  report,  we  examined  the  expression  of  IL-17 
within gastric adenocarcinoma tumors and the rela-
tionship between IL-17-postive cells and gastric ade-
nocarcinoma patient prognosis. This is the first report 
on the potential for IL-17 to serve as a prognostic in-
dicator in gastric cancer. We used immunohistoche-
mistry to characterize the intratumoral IL-17-postive 
c e l l s   a n d   C D 8 +  cytotoxic  T  lymphocytes  in  gastric 
adenocarcinoma patients after resection and analyzed 
the association between prognosis and the detection 
of IL-17-postive cells and CD8 + TILs. 
For the present study,  we collected 192 gastric 
adenocarcinoma samples; 90.6% (174/192) expressed 
IL-17,  which  was  distributed  throughout  the  cytop-
l a s m .   I n   t h e   C D 8 + positive cells, CD8 was extensively 
expressed on the membrane. We further analyzed the 
relationship  between  intratumoral  IL-17  expression, 
CD8+ TILs and the clinic pathologic features in pa-
tients with gastric adenocarcinoma. IL-17 expression 
was  significantly  correlated  with  age  (p=0.004);  the 
expression of IL-17 is significantly higher in younger 
patients. There was no significant association between 
the  expression  of  IL-17  and  other  clinic  pathologic 
features. Of note, we found no statistically significant 
correlation between the expression of IL-17 and UICC 
staging (p=0.883) or histologic grade (p=0.510), even 
though  some  other  studies  have  shown  that  an  in-
crease in Th17 cells was associated with clinical stage 
in blood [10] and in tumor tissue [18].  
Kaplan-Meier survival analysis showed that the 
five-year overall survival probability among patients 
with  higher  levels  of  IL-17  was  significantly  better 
than  those  with  lower  levels  of  IL-17  expression 
(p= 0 . 0 3 6 ) .   T h i s   i s   c o n s i s t e n t   w i t h   a   r e c e n t   r e p o r t   o n  
human ovarian cancer [8]. However, in HCC patients, 
Z h a n g   [ 1 9 ]   e t   a l .   o b s e r v e d  that increased intratumoral 
IL-17-p o s t i v e   c e l l s   c o r r e l a t e   w i t h   p o o r   s u r v i v a l .   T h e  
different types of tumors and immunological statuses 
may contribute to different results. While there was 
no significant correlation between the level of CD8+ 
TILs and patient survival (p=0.366), CD8+ T lympho-
cytes are thought to be at the forefront fighting against 
tumors,  and  the  number  of  CD8+  TILs  was  signifi-
cantly correlated with UICC staging (p=0.012) in this 
s t u d y .   H o w e v e r ,   t h e y   h a v e   n o   p r o g n o s t i c   v a l u e   i n  
many  cancer  types.  Our  results  are  consistent  with 
several previous reports [20-21]. 
 T h r o u g h   c o r r e l a t i o n   a n a l y s i s ,   w e   f o u n d   n o   s i g-
n i f i c a n t   c o r r e l a t i o n   b e t w e e n   t h e   e x p r e s s i o n   o f   I L -17 
and CD8+ TILs (p=0.348, Figure 4). Studies regarding 
t h e   m e c h a n i s m s   b y   w h i c h   I L -17 mediates tumor im-
munity have shown that IL-1 7   c a n   r e c r u i t   T h 1 -related 
chemokines,  such  as  CXCL9  and  CXCL10,  which 
p r o m o t e   t h e   m i g r a t i o n   o f   e f f e c t o r   T   c e l l s   t o   t h e   t u m o r  
site. Levels of CXCL9 and CXCL10 directly correlate 
w i t h   t h e   n u m b e r   o f   t u m o r -infiltrating  CD8+ T  cells. 
IL-17 plays an indirect role in antitumor immunity by 
promoting effector CD8+ T   c e l l s   [ 8 ] .   S i n c e   o u r   s t u d y  
d i d   n o t   s h o w   s i g n i f i c a n t   c o r r e l a t i o n   b e t w e e n   C D 8   T  
cells and IL-1 7 ,   t h e   r e s u l t s   o f   o u r   r e p o r t   m a y   s u g g e s t  
that  intratumoral  expression   o f   I L -17  may  involve 
other mechanisms and anti-tumor effector cells alter-
n a t i v e   t o   t h e   p r e s e n c e   o f   C D 8   T   c e l l s .  While He D et al 
[ 2 2 ]   o b s e r v e d   t h a t   I L -17R  deficiency  caused  an  in-
crease in CD8 T cell infiltration in an IL-17R-deficient 
mice model, the infiltration of myeloid-derived sup-
pressor cells (MDSCs) are reduced in tumors. These 
controversial data about IL-17 in tumor development 
have reflected the complication in tumor microenvi-
r o n m e n t .   M a n y   f a c t o r s ,   i n c l u d i n g   t h e   t y p e s   o f   t u m o r  
and the microenviron m e n t   o f   t h e   t u m o r   i t s e l f   ,   m a y  
lead to different endpoints. 
I n   s u m m a r y ,   o u r   r e s u l t s   s h o w   t h a t   I L -17  and 
CD8+ TILs are generally present in gastric adenocar-
c i n o m a .   W e   a l s o   f o u n d   t h a t   I L -1 7   e x p r e s s i o n   i s   c o r r e-
l a t e d   w i t h   a g e   ( p=0.004) and that CD8+ TILs are cor-
r e l a t e d   w i t h   U I C C   s t a g i n g   ( p=0.012)  and  depth  of 
tumor  invasion  (p=0.022). Multivariate Cox propor-
tional hazard analyses revealed that IL-17 and recur-
rence are independent factors affecting the five-year 
o v e r a l l   s u r v i v a l   p r o b a b i l i t y .   O u r   s t u d y   s u g g e s t s   that 
the expression levels of IL-1 7   i n   t h e   t u m o r   c a n   b e   a n  
independent  prognostic  indicator  in  gastric  adeno-
carcinoma  patients.  The  molecular  mechanisms  for 
this correlation, which may help us better understand 
t h e   r o l e   o f   I L -17 in the development of gastric adeno-
carcinoma, remain to be elucidated. 
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